Max W. Sung

Max Sung practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Max Sung's NPI, 1487672044, was assigned on July 18, 2006. Max Sung graduated from Albert Einstein College of Medicine in 1980. Max Sung's New York license number on file is 153309.

Max Sung's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Max Sung also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Max Sung's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Max Sung to 1 more home health agency, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Max Sung practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Max Sung's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Max Sung is board certified in internal medicine by the American Board of Internal Medicine. Max Sung has a license on file in New York.

Dmand AI lists chronic leukemia, colorectal cancer, neutropenia, prostate cancer and purpura and thrombocytopenia among the conditions Max Sung treats.

CMS data shows 398 Medicare services from Max Sung across 3 procedure codes in 2024, all of them office visits, for 100 Medicare patients. Medicare paid $42,658 for them.

CMS counts 100 Medicare patients who saw Max Sung in 2024. The largest group is 65 to 74, with 50 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 2.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Max Sung's median patient age at 69, with 34% women.

In 2024, Max Sung wrote 446 Medicare Part D claims for 82 patients. 78% of them were for generic drugs. CMS names the drug for 187 of them, across 12 drugs with 11 or more claims each, at $914,982 in total drug cost. In 2023, CMS named 273 claims across 15 drugs.

Max Sung accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Max Sung as offering telehealth.

Dmand AI links 54 papers to Max Sung, published from 2009 to 2024. 2020 was the busiest year, with 5. The most frequent topics are Liver Neoplasms, Carcinoma, Hepatocellular and Antineoplastic Agents. Max Sung has published most often in Cancer. Max Sung's most frequent co-authors are Myron Eliot Schwartz, MD, Johnny Kao, MD and Ari D. Baron, MD.

Dmand AI links Max Sung to 3 clinical trials. Conditions studied include Breast Neoplasms, Rectal Neoplasms and Breast Diseases.

CMS Open Payments shows 74 general payments to Max Sung from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Eisai Inc. paid the most, $17,723. It also lists 1 research payment totaling $676 in 2022.

Max Sung graduated from Albert Einstein College of Medicine in 1980.

Max Sung is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.